Last updated: 08/12/2026 09:00:25
Kidney Impairment in Participants With Systemic Lupus Erythematosus on Belimumab Versus Standard of Care
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Finalized
Finalized
Trial overview
Official title: Evaluating Decline in Kidney Function in a Real-World Population of Patients with Systemic Lupus Erythematosus Treated with Belimumab Versus Standard of Care
Trial description: This study will evaluate the impact of belimumab (as compared to standard of care [SOC]) on decline in kidney function among adult participants with SLE in the United States (US). The index date will be the date of the first prescription for belimumab or SOC. The first month after the index date will serve as the washout period for participants.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Percent Change in eGFR from Baseline to Observation Period Before SMR Weighting
Timeframe: From 12 months before index date up to 12 months after index date
Percent Change in eGFR from Baseline to Observation Period After SMR Weighting
Timeframe: From 12 months before index date up to 12 months after index date
Secondary outcomes:
Time to Worsened Kidney Impairment Before SMR Weighting
Timeframe: Up to 87 months from index date
Time to Worsened Kidney Impairment After SMR Weighting
Timeframe: Up to 87 months from index date
Time to Initiation of Lupus Nephritis (LN) Induction Therapy Before SMR Weighting
Timeframe: Up to 87 months from index date
Time to Initiation of Lupus Nephritis (LN) Induction Therapy Before SMR Weighting
Timeframe: Up to 87 months from index date
Interventions:
Not applicable
Enrollment:
Not applicable
Observational study model:
Cohort
Primary completion date:
2025-06-10
Time perspective:
Retrospective
Clinical publications:
Not applicable
Medical condition
Lupus Nephritis
Product
belimumab
Collaborators
Not applicable
Study date(s)
December 2023 to October 2025
Type
Observational
Phase
4
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- For the belimumab cohort, initiation of a prescription for Intravenous (IV) or Subcutaneous (SC) belimumab between 01-Jan-2017 and 31-Mar-2023 (defines the index date).
- For the SOC cohort without prior belimumab use, the earliest occurrence of any of the following three clinical activities between 01-Jan-2017 and 31-Mar-2023 will qualify for inclusion and define the index date. For those with prior belimumab use, the earliest of any of these activities on or after the discontinuation of belimumab will define the index date:
- For the belimumab cohort, those on belimumab monotherapy (that is [i.e.], exclude those with no prescriptions for any SLE therapy, including immunosuppressants, steroids, or antimalarials in the past 6 months)
- Diagnosis of drug-induced lupus any time before the index date
Inclusion and exclusion criteria
Inclusion criteria:
- For the belimumab cohort, initiation of a prescription for Intravenous (IV) or Subcutaneous (SC) belimumab between 01-Jan-2017 and 31-Mar-2023 (defines the index date).
- For the SOC cohort without prior belimumab use, the earliest occurrence of any of the following three clinical activities between 01-Jan-2017 and 31-Mar-2023 will qualify for inclusion and define the index date. For those with prior belimumab use, the earliest of any of these activities on or after the discontinuation of belimumab will define the index date:
- Initiation of an immunosuppressant (either first time use or switching to a new immunosuppressant) for the treatment of systemic lupus erythematosus (SLE)
- Initiation of IV corticosteroids
- Initiation or dose escalation of oral corticosteroids (OCS) to a prednisone-equivalent dosage >=20 milligram per day (mg/day) for participants who never had a dose >=20 mg/day during the Baseline period.
- As OCS may have different dosage forms, doses of different OCS will be converted to equivalent prednisone strengths for the calculation of expected daily dose. These conversions will be based on the potencies and duration of action of the OCS. The conversions for the equivalent dose of each OCS to 7.5 mg of prednisone were extracted from the literature and medical references, and the conversion table.
- Diagnosis of SLE at any time before or on the index date based on
- >=2 outpatient medical records at least 60 days apart, OR
- >=1 inpatient/ Emergency Room (ER) record
- Age >=18 years on the index date
- >=12 months of continuous enrollment before and after the index date
- For the analyses of percent change in eGFR and time to worsened kidney impairment outcome, participants are also required to have at least one eGFR measurement during the Baseline period and during the observation period. In addition, participants in the analysis of percent change in eGFR will be required to not switch treatment cohorts for at least 12 months after the index date.
Exclusion criteria:
- For the belimumab cohort, those on belimumab monotherapy (that is [i.e.], exclude those with no prescriptions for any SLE therapy, including immunosuppressants, steroids, or antimalarials in the past 6 months)
- Diagnosis of drug-induced lupus any time before the index date
- Diagnosis of active central nervous system lupus any time before the index date
- Diagnosis of lupus nephritis (LN) prior to the index date
- Initiation of LN induction therapy prior to the index date
- Prescription for the index therapy within the 12 months preceding the participant’s index date (for those who qualify for more than one treatment cohort, this applies only to the first index date)
- Prescription for anifrolumab during the 12-month baseline period
- Participants with a diagnosis of polycystic kidney disease or kidney cancer
Trial location(s)
No location data available.
Study documents
Protocol
Available language(s): English
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Finalized
Actual primary completion date
2025-06-10
Actual study completion date
2025-06-10
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website